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Every year, the Joint United Nations Programme on
HIV/AIDS (UNAIDS) produces estimates that chart the
magnitude of the worldwide HIV epidemic, its impact
and the progress taken to curb its spread and reduce its
impact. The UNAIDS Reference Group on Estimates,
Modelling and Projections [1] exists to review and
develop the methods supported by UNAIDS to generate
national estimates of HIV and related indicators.
UNAIDS and its Reference Group routinely produce
special editions of scientific journals to document the
methods used to produce the UNAIDS estimates and to
provide updates on the directions the methods are
expected to take in the future [2–6].
The work of the Reference Group is two-fold – to
continually calibrate, update and validate the methods,
while simultaneously extending the methods to take
advantage of new data sources, and to adapt approaches so
as to maximise their usefulness to country programme
planning and in evaluation. The articles in this
supplement fall into both of these categories. Two
articles document recent improvements to the estimation
and projection models that are used, and another
compares the UNAIDS estimates with other sets of
published estimates and data. Several other articles show
how the methods have expanded to accommodate the
need to better understand data requirements for young
children and older people; howestimates of key indicators
are produced at finer spatial scales; and finally, how
methods can and will synthesise newly available data into
estimates. We address each of these topics in turn below.
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inform and assist programme planners and decision
makers, as well as scientists, researchers and the wider
public.Developments in the estimation tools
The Estimation and Projection Package (EPP) and the
AIDS Impact Module (AIM) in Spectrum were used by
158 countries to produce the 2013 estimates of HIV and
HIV-related indicators [7]. EPP and Spectrum are the
core set of tools used by UNAIDS and are continually
under development. Brown et al. [8] describe the three
models that can be fit to prevalence data in EPP– r-spline,
r-trend and EPP classic. This new repertoire of models
should enable many types of epidemic trajectory to be
captured and uncertainty in the shape of the epidemic
curve represented where data are sparse. Stover et al. [9]
describe, among other changes, how the AIM module
now includes a procedure whereby, in large epidemics,
the total death rate is made consistent with published
projections through modification of background
mortality rates where necessary. Another important
update is in the methods used for estimating the number
of orphans, which now include the changing effects of
antiretroviral therapy (ART) and prevention of mother-
to-child transmission (PMTCT) programmes over time as
guidelines have changed [9]. Lastly, Stover et al. [9]
describe how ART need based on the new WHO
guidelines (reflecting recommendations for ART
initiation regardless of CD4þ cell count for serodiscor-
dant couples, HIV-positive pregnant women and all
HIV-positive children under 5 years, among others) can
be reflected in the model.Health, Faculty of Medicine, Imperial College London, bMRC
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cerned that models were not fully incorporating infor-
mationontheexcessdeathratesexperiencedbypeoplewho
inject drugs (PWID). In response to these concerns,
Mathers andDegenhardt [10]updatedaprevious systematic
review [11] to examine non-AIDS mortality in PWID.
Theyexamine differential effects of non-AIDSmortality in
PWID by region, income status, sex, HIV status and
whether opioid substitution therapy is used. Non-AIDS
mortality in HIV-positive PWID (at 2.51 per 100 person-
years) was found to be 1.5 times higher than among HIV-
negative PWID (at 1.66 per 100 person-years). Although
additional differences appear to exist, more representative
data are required, particularly in low-income and middle-
income countries, to improve model estimates.
A new focus on young children and older
adults
Originally, estimates were published only for adults 15–49
years. This focus has expanded over time in parallel with
the epidemic ageing into older age groups andwith cohorts
of children infected. Maternal and child health is a major
global priority, andHIVplays a significant role, particularly
in sub-Saharan Africa. Understanding trends in paediatric
infections and theneed forART in this group is critical, not
only for health systems and programme management, but
also for planning future drug procurement and develop-
ment. Penazzato et al. [12] explore different plausible
scenarios to estimate the potential future need for
paediatric ART. They find that, even under the most
optimistic prevention scenarios, by 2020 there will be
nearly 2 million children living with HIV, signifying the
importance for age-appropriate drug regimens.
It is becoming increasingly important to better understand
the size of the older population living with HIV. In sub-
Saharan Africa, where the burden of infection is greatest,
surveillance in older populations has been limited. Mahy
et al. [13] present estimated trends in prevalence over time
showing that HIV prevalence among those aged over 50
years has increased considerably over time. However, there
still appear to be some discrepancies between national
surveys and estimates, which underline the need for
expanded surveillance in older populations to improve the
programmatic response and to better understand the health
needs of this population.Estimates that are responsive to
programme managers needs
Countries require programme-relevant information at
sub-national levels to support local planning, decision
making and resource allocation. With the tools available
at present, it is possible to produce estimates at finer
geographic levels. For example, Mahy et al. [14] describe
the process of producing state-level estimates in Nigeriausing EPP and Spectrum and the challenges that result
from using the more limited data available at this level and
issues in model selection for each state. In the future,
hierarchical and spatial models may allow researchers to
better address these limitations.
The spatial distribution of people living with HIV in sub-
Saharan Africa, at a much finer resolution, is described
by Larmarange and Bendaud [15] using an approach
that combines geolocation information from national
population-based surveys with estimates of prevalence
from EPP/Spectrum. This approach represents an initial
phase of method development to represent spatial
variation in order to better understand heterogeneity
across national epidemics and has already had an impact in
how programme managers are able to understand the
epidemics they face.
New methods have also been added that allow the
incidence of tuberculosis disease among HIV-positive
persons to be estimated. Tuberculosis and HIV coinfec-
tion is a Millennium Development Goal target indicator
for countries in sub-Saharan Africa but, until now,
estimates have only been made at the regional level and
have not necessarily been integrated with the data
available on HIV epidemics. Here, Pretorius et al. [16]
detail the methods used to estimate tuberculosis–HIV
incidence and mortality at the country level allowing for
coherence between existing tuberculosis incidence and
mortality estimates [17], while leveraging other HIV
estimates, such as HIV prevalence and the CD4þ cell
count distribution of the HIV-infected population. This
part of the model will expand in the future to incorporate
additional tuberculosis data to improve these estimates.Leveraging more data sources to
strengthen estimates
A key aim for ongoing method development is to
incorporate all available data sources to strengthen
estimates. To date, estimates coordinated by UNAIDS
have largely relied on surveillance data (particularly data
from women attending antenatal care (ANC) and from
targeted surveys among key populations) and national
survey data (e.g. household-based Demographic and
Health Surveys) to inform both the overall trends and the
level of HIV prevalence. In concentrated epidemics,
many countries do not have all the data required
(including nationally representative data for key popu-
lations and size estimates), but do have additional data
sources such as detailed case report and vital registration
data which may be used to better inform estimates.
Stover et al. [9] describe a new approach used in
Argentina, Mexico and Brazil for their 2013 estimates
whereby incidence trends, based on fits to prevalence
data, are selected to better match programme estimates of
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deaths due to HIV/AIDS. Another method which does
not rely on prevalence data and size estimates of key
populations but instead utilises only case report data to
estimate incidence is described by Vesga et al. [18] and
applied in Colombia. For the same reason of aiming to
leverage additional data to check projections, the new
version of EPP includes a procedure for comparing
estimates, with ad hoc data on AIDS case reports and
small local surveys, which have been assembled into a
database [8]. These approaches are intended to bring
historical estimates of new HIV infections and AIDS
deaths in better alignment with other national data. It is
expected that use of these approaches will increase in the
future as the methods are further developed and refined,
and additional data sources are integrated.
Brown et al. [8] and Marsh et al. [19] describe how
national population-based surveys are now directly
included in the fitting process in EPP, which allows
survey trends to inform the fitting and allows for more
appropriate representation of uncertainty. Marsh et al.
[19] additionally analyse prevalence in national surveys
compared with ANC prevalence to derive updated
calibrations for ANC data in countries without a national
population-based survey. In order to further examine
how these two data sources (ANC data and household
surveys) should be considered together, Eaton et al. [20]
compare prevalence trends among pregnant women with
prevalence trends among all women in the general
population. The authors illustrate that, in sub-Saharan
Africa, over time the age distribution of HIV prevalence
has shifted towards older women, who are less likely to
become pregnant and be captured in ANC surveillance,
so that observed ANC prevalence trends could have
exaggerated the extent to which HIV prevalence in
the general population has declined. This would have
important implications for use of ANC data to inform
population-level trends. Age-structured modelling fra-
meworks that explicitly account for fertility schedules
may be less susceptible to these issues and are a significant
avenue for further investigation.
Incidence assays are an additional potential source of data
which may strengthen estimates by providing cross-
sectional measures of incidence. While some countries
have already used incidence assays, more countries are
planning for their inclusion in future national population-
based surveys. Bao et al. [21] present methods that
incorporate incidence assays, or combinations of assays,
into the fitting process in EPP. The authors illustrate how
the effect of including assays is largely dependent on the
sample size and the calibrating parameters of the assay (the
false recent rate and the mean duration of recent
infection). Data from assays used in a single survey with
small sample sizes will have only a modest effect on
informing estimates and results may be biased if the
calibrating parameters are not accurate. However,the added value of these assays is expected to increase
in the future with multiple measures of incidence and
improved calibrating parameters.
The use of different data sources and methods for
estimation can lead to different results. Hallett et al. [22]
compare estimates of HIV incidence, prevalence and
mortality from the Global Burden of Disease (GBD)
Study 2013 [23] with UNAIDS estimates, and triangu-
lates these estimates with other data where available. The
authors illustrate how HIV incidence estimates from the
GBD Study 2013 are substantially lower than HIV case
report data in countries with strong surveillance systems
including the United States, the United Kingdom,
Australia and France among others. The mortality trends
in the Murray et al. [23] study suggest a much shallower
reduction in the era of ART thanUNAIDS has estimated.
Population-based cohorts, however, offer the opportu-
nity to examine real trends in mortality, albeit in selected
small locations. Reniers et al. [24] in this supplement
present trends in mortality among people living with HIV
from population-based cohort studies in East and
Southern Africa which illustrate declines in mortality
rates of more than 50% in the ARTera compared with the
pre-ART era.
The work of bringing more data sources to bear on the
estimates is ongoing and is intended to strengthen future
sets of estimates produced by UNAIDS. Additional data
sources that will become integrated in the coming rounds
of methods revisions may also include data from HIV
testing of pregnant women in PMTCT programmes. The
Reference Group also calls for further data collection
especially related to ART: confirmed numbers of new
initiators, numbers currently in care, age distributions
and CD4þ cell counts at ART initiation, among other
factors.
In conclusion, UNAIDS supports and empowers
countries to develop their own estimates, simultaneously
harnessing local knowledge and understanding of
epidemics and fostering the routine application of the
estimates in programme planning. The studies in this
collection emphasise the dynamic nature of the methods
that are used to produce the UNAIDS estimates. Further
changes can be expected in the coming years as new data
sources become available, additional opportunities to
validate the estimates present themselves, and the needs of
programme managers continue to evolve.Acknowledgements
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